Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer


Shangze Li
May 15, 2019; 79:2580-2592
Prognostic Factors and Biomarkers – Preclinical

Powered by WPeMatico

Leave a Reply